omnadren 250

The capsules should be taken orally one or two times a day, regardless of mealtime with water. Do not open the capsule.The recommended omnadren 250 dose is 220 mg 1 time per day (2 capsules of 110 mg).

In patients with moderate renal impairment due to the risk of bleeding, the recommended dose is 150 mg 1 time per day (2 capsules of 75 mg).

Prevention of VTE after total knee replacement: the use PRADAKSA preparation should begin in 1-4 hours after the operation is completed with the reception 1 capsule (110 mg), followed by increasing doses up to 2 capsules (220 mg) once a day for the next 10 days. If hemostasis is not achieved, treatment should be delayed. If treatment is not started on the day of surgery, therapy should start with two receiving capsules (220 mg) once daily.

Prevention of venous thromboembolism after total hip replacement: application PRADAKSA drug should be started within 1-4 hours after completion of receiving operation with one capsule (110 mg), followed by increasing doses up to 2 capsules (220 mg) once daily for the next 28-35 days. If hemostasis is not achieved, treatment should be delayed. If treatment is not started on the day of surgery, therapy should start with two receiving capsules (220 mg) once daily.

Prevention of stroke, systemic thromboembolism and reduced cardiovascular mortality in patients with atrial fibrillation:

PRADAKSA recommended to use the drug in a daily dose of 300 mg (1 capsule in 150 mg 2 times a day). Therapy should be continued for life.

Use in special patient groups

Use in children

In patients under 18 years of efficacy and safety not studied, therefore use in children is not recommended (see. “Contraindications”).

Impaired Renal Function

Before therapy, in order to avoid the appointment of the drug in patients with severely impaired renal Functions (CC less than 30 ml / min), you must first estimate the creatinine clearance. In the absence of data on the use of the drug in patients with severe renal impairment (creatinine clearance less than 30 ml / min) use PRADAKSA drug is not recommended (see. “Contraindications”).

Renal function should be assessed in the treatment process, when there is a suspicion of a possible reduction or deterioration of renal function (eg, hypovolemia, dehydration, concomitant use of certain medications, etc.).

In applying the drug  the purpose of the prevention of venous thromboembolism in patients undergoing orthopedic surgery with moderate renal impairment (creatinine clearance 30-50 ml / min)daily dose should be reduced to 150 mg (2 capsules of 75 mg 1 time per day).

In applying the drugomnadren 250 for the purpose of prevention of stroke, systemic thromboembolism and reduce cardiovascular mortality in patients with atrial fibrillation with moderate renal impairment (creatinine clearance 30-50 ml / min) dose adjustment is required. Recommended use of the drug in a daily dose of 300 mg (1 capsule 150 mg 2 times a day). Renal function should be assessed at least once a year.

Dabigatran appears in hemodialysis; however, clinical experience in patients undergoing dialysis, limited.

Use in elderly patients

Due to the fact that increasing the exposure of the drug in elderly patients (above 75 years old) often caused by decreased renal function prior to administration of the drug necessary to assess renal function.Renal function should be assessed at least once a year or more frequently, depending on the clinical situation. Correction of the dose should be based on the severity of renal dysfunction (see. “Renal impairment”).

Prevention of venous thromboembolism in elderly patients (over 75 years) after orthopedic surgery : application experience is limited. The recommended dose – 150 mg (2 capsules of 75 mg once daily).

In applying the drug  in elderly patients older than 80 years with the aim of prevention of stroke, systemic thromboembolism and reduce cardiovascular mortality in patients with atrial fibrillationdrug PRADAKSA should take a daily dose of 220 mg (1 capsule of 110 mg 2 times a day).

Effect of body weight

No dose adjustment is required, depending on body weight.

While the use of amiodarone, quinidine or verapamil, the dose of the drug PRADAKSA should be reduced to 150 mg 1 time per day (2 capsules of 75 mg) (see. “Interaction with other medicinal products” section).

Patients taking the drug omnadren 250 after orthopedic surgery, it is not recommended to start at the same time the use of verapamil and connect it to the therapy in the future.

Prevention of stroke, systemic thromboembolism and reduced cardiovascular mortality in patients with atrial fibrillation:

No dose adjustment is required, patients are advised to use the drug in a daily dose of 300 mg (1 capsule in 150 mg 2 times a day).

Use in patients with an increased risk of bleeding

Prevention of stroke, systemic thromboembolism and reduced cardiovascular mortality in patients with atrial fibrillation:

The presence of such factors as the age of 75 years or older, a moderate decrease in renal function (creatinine clearance 30-50 ml / min), the simultaneous use of inhibitors of P-glycoprotein, or an indication of gastrointestinal bleeding history can increase the risk of bleeding (see. “Cautions “). Patients with one or more of these risk factors in the physician’s discretion, may reduce the daily dose to PRADAKSA 220 mg (1 capsule receiving 110 mg 2 times a day).

The transition from the use of the drug  to parenteral anticoagulants.

Prevention of venous thromboembolism in patients undergoing orthopedic surgery: parenteral administration of anticoagulants should be started within 24 hours after the last dose of the drug . anabolic steroids online pharmacy

testosterone cypionate for sale

online anabolic steroids